USPTO Patent US12582642B2 for Treating Bovine Papillomatosis
Summary
The USPTO has granted patent US12582642B2 to KINOPHARMA, INC. for a composition and method to treat bovine papillomatosis. The patent covers compounds represented by Formula (I) or their pharmaceutically acceptable salts.
What changed
The United States Patent and Trademark Office (USPTO) has issued patent US12582642B2 to KINOPHARMA, INC. This patent covers a composition containing a specific compound (Formula I) or its pharmaceutically acceptable salt, intended for the treatment, amelioration, and/or suppression of bovine papillomatosis caused by bovine papillomavirus. The patent also includes a method for administering this compound to cows.
This is a grant of intellectual property and does not impose new regulatory obligations on entities outside of those involved in the patent holder's operations or potential licensees. Companies in the veterinary pharmaceutical sector may wish to review the patent claims for potential licensing opportunities or to ensure their own research and development activities do not infringe upon this granted patent. No immediate compliance actions are required for most entities.
Archived snapshot
Mar 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Composition for treating, improving, and/or preventing progression of bovine papillomatosis caused by bovine papillomavirus
Grant US12582642B2 Kind: B2 Mar 24, 2026
Assignee
KINOPHARMA, INC.
Inventors
Hiroshi Onogi, Tomas Javier Acosta Ayala
Abstract
Provided are a composition for treatment and the like of bovine papillomatosis caused by bovine papillomavirus, and a method using the same. Provided are a composition for treatment, amelioration, and/or suppressing the progression of bovine papillomatosis caused by bovine papillomavirus, the composition containing, as an active ingredient, a compound represented by Formula (I) below or a pharmaceutically acceptable salt of the compound; and a method for treating, ameliorating, and/or suppressing progression of, bovine papillomatosis caused by bovine papillomavirus, the method including administering, to a cow, a compound represented by Formula (I) below or a pharmaceutically acceptable salt of the compound:
CPC Classifications
A61K 31/4545 A61P 17/02
Filing Date
2021-05-28
Application No.
17928848
Claims
9
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.